The expression of serum sEGFR, sFlt-1, sEndoglin and PLGF in preeclampsia

Autor: Zitao Liu, Chang Shu, Chengguo Wei, Jin He, Weihua Tong, Lifeng Cui, Xiu-Fen Liu, Miao Cui, Yulin Li, Fei Ye, Jinghai Hu, David Y. Zhang, Jing Jiang, Jian Jenny Tang
Rok vydání: 2018
Předmět:
0301 basic medicine
Adult
Blood Pressure
Enzyme-Linked Immunosorbent Assay
Gestational Age
Severity of Illness Index
Preeclampsia
Andrology
03 medical and health sciences
Young Adult
0302 clinical medicine
Pre-Eclampsia
Predictive Value of Tests
Pregnancy
Risk Factors
Internal Medicine
medicine
Birth Weight
Humans
Soluble Epidermal Growth Factor Receptor
Soluble endoglin
Placenta Growth Factor
reproductive and urinary physiology
Biochemical markers
030219 obstetrics & reproductive medicine
Fetal Growth Retardation
Vascular Endothelial Growth Factor Receptor-1
medicine.diagnostic_test
Growth retardation
business.industry
Matched control
Endoglin
Infant
Newborn
Obstetrics and Gynecology
medicine.disease
Microarray Analysis
female genital diseases and pregnancy complications
ErbB Receptors
030104 developmental biology
Immunoassay
Case-Control Studies
embryonic structures
Infant
Small for Gestational Age
Premature Birth
Female
business
Biomarkers
Zdroj: Pregnancy hypertension. 13
ISSN: 2210-7797
Popis: The objective of this study was to investigate soluble epidermal growth factor receptor (sEGFR), soluble vascular endothelial growth factor receptor 1 (sFlt-1), soluble endoglin (sEndoglin) and placenta growth factor (PLGF) concentrations in normotensive, preterm and term preeclamptic pregnancies' serum and thus to specify the clinical utility of these biochemical markers in monitoring severity and intrauterine growth retardation of preterm preeclampsia. 172 pregnant women were divided into the following groups: preterm preeclampsia, preterm control, term preeclampsia and term control. Preterm preeclampsia patients were stratified with severe feature (n = 50) and without severe feature (n = 22). sEGFR, sEndoglin and PLGF were assessed using Luminex multiplex immunoassay, whilesFlt-1 was assessed using ELISA. sEGFR was significantly lower in preterm preeclampsia than matched control (p 0.001) and mildly lower in term preeclampsia than matched control (p 0.01). On contrary, sFlt-1 was significantly higher in preterm preeclampsia than matched control (p 0.001) and mildly higher in term preeclampsia than matched control (p 0.01). sFlt-1, sFlt-1/sEGFR and sFlt-1/PLGF were positively correlated with the severity of preterm preeclampsia (P 0.001, R value ≥ 0.6), especially sFlt-1/sEGFR had the highest R value (R value = 0.711) among them. Furthermore, sEndoglin and the ratio of sEndoglin/sEGFR were associated with neonatal birth weight small for gestational age (SGA, n = 25) in preterm preeclampsia group.The ratio of sFlt-1/sEGFR could be used as a novel candidate biochemical marker in monitoring the severity of preterm preeclampsia. sEndoglin and sEGFR may be involved in the pathogenesis of SGA in preterm preelampsia.
Databáze: OpenAIRE
Externí odkaz: